Today: October 19, 2017, 12:11 am
  
Health

PromarkerD can predict Diabetic Kidney Disease better than any Current Measure

PromarkerD can predict Diabetic Kidney Disease better than any Current Measure
PR-Inside.com: 2017-06-12 12:00:28
- PromarkerD predicted 86% of disease-free patients who went on to develop chronic kidney disease within four years

- Largest prospective clinical study on diabetic kidney disease in the community, evaluating 792 patients over 4yr period

- Presented at American Diabetes Association's 77th Annual Scientific Sessions, 9-13th June in San Diego

SAN DIEGO, CA, June 12, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd ('PILL', ASX: PIQ), a global leader in applying proteomics to MedTech, has announced results from the clinical validation study showing that its PromarkerD blood test can predict the onset of diabetic kidney disease (DKD) better than any current measure.


The findings were presented by Professor Tim Davis, from The University of Western Australia Medical School, at the American Diabetes Association's 77th Annual Scientific Sessions (ADA), 9-13th June, in San Diego, California. (ADA Abstract #2017-LB-7091-Diabetes)

The study, undertaken as a joint collaboration between Proteomics International and The University of Western Australia, is the largest prospective clinical study on diabetic kidney disease in the community and evaluated the clinical utility of PromarkerD with 792 patients.

In March, Frost & Sullivan identified PromarkerD as the world's leading test for diabetic kidney disease, and the new results confirm PromarkerD predicts rapid decline in kidney function in type 2 diabetes, across clinically significant definitions of disease, independently of recognised clinical risk factors.

According to the International Diabetes Federation, 415 million adults had diabetes in 2015. The US Center for Disease Control states that one in three adult diabetics have chronic kidney disease, or 138 million people today. Once detected, chronic kidney disease can be treated through medication and lifestyle changes to slow down the disease progression, and to prevent or delay the onset of kidney failure.

The International Diabetes Federation further predicts the number of diabetics will rise to 642 million by 2040, which, if unchecked, will increase the number of adults with chronic kidney disease by 76 million to 214 million. The current cost of dialysis is estimated at $100,000 per person per year.

The validation study (assessing the performance of the prediction model in an independent population) confirms results from the original development study, also completed in collaboration with Professor Davis. Initial findings on the diagnostic performance of PromarkerD were published in the European Journal of Proteomics in March 2017.

In the four-year prospective study, the three protein marker (biomarker) blood test (PromarkerD) predicted 86% of previously disease-free patients who went on to develop chronic kidney disease (Sensitivity 86%, Specificity 78%, AUC 0.88). In comparison to the development study, the results from the larger validation study showed slightly lower levels of predictive ability (development 95%), however, it achieved a 10% improvement in levels of false positives.

Professor Davis concluded, "The data support the use of the protein biomarker panel in conjunction with eGFR (estimated glomerular filtration rate) in patients with type 2 diabetes to monitor and predict their decline in kidney function."

"This large clinical study validates the important role of the PromarkerD test to effectively monitor patients with diabetes," said Dr Richard Lipscombe, Managing Director of Proteomics International. "Although patients may appear to be adequately controlled for the complications of diabetes, current tests do not reveal early symptoms of kidney disease, which can result in the need for dialysis or kidney transplant."

The annual ADA Scientific Sessions are the world's largest and most prominent meeting of diabetes experts, attracting more than 13,000 delegates. The results were reported in the Late-breaking Abstracts section of the conference, titled "Novel Circulating Biomarkers Predicting Rapidly Declining Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study". PILL's head of business development Chuck Morrison is also attending the event.

PromarkerD - a predictive diagnostic test for diabetic kidney disease (www.PromarkerD.com)

PromarkerD is a breakthrough blood test that uses a protein 'fingerprint' to measure kidney disease in patients with diabetes. This ground-breaking test can both diagnose and predict disease. A published study in a peer-reviewed journal has shown that for diabetic patients already suffering from chronic kidney disease PromarkerD can diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).

Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In the current study 792 patients were followed in dual, four-year longitudinal clinical studies. PromarkerD correctly predicted 86% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.

The Frost & Sullivan report titled "Biomarkers Enabling Diabetes and Obesity Management" is available via PILL's website (www.proteomicsinternational.com).

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 741 Words
Related Articles
More From The Author
BlackGold, China Huadian Outline Riau 1 Project [..]
SINGAPORE, June 12, 2017 - (ACN Newswire) - BlackGold Natural Resources Limited (the "Company", and together with its [..]
CardPay to Accept JCB eCommerce in SEPA
TOKYO, June 9, 2017 - (ACN Newswire) - JCB International Co., Ltd. (JCBI), the international operations subsidiary of JCB, is [..]
Human Heart Tissue Grown from Stem Cells [..]
SINGAPORE, June 8, 2017 - (ACN Newswire) - Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have [..]
Ceremony of 'Quam IR Awards 2016' Successfully [..]
HONG KONG, May 31, 2017 - (ACN Newswire) - The award presentation ceremony of Quam IR Awards 2016 (QIRA) successfully [..]
Electroplating Engineers of Japan Develops Innovative Direct [..]
- New technology overcomes issues of existing metallic inks and enables low-resistance wire formation using low-temperature process [..]
 
More From Health
“Reverse Abscopal Effect” in Rheumatoid Arthritis Using [..]
Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem [..]
Air Optix Aqua Contacts from Alcon Keeps [..]
Alcon Laboratories’ Air Optix Aqua 6 pack contact lenses bring together two advanced technologies designed to provide long-lasting [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.